Approved amyloid-clearing therapies slow early Alzheimer’s progression but don’t stop it, and that gap is exactly where Merry Life Biomedical is placing its bet. The Taiwan-based company is advancing TML-6, an oral investigational drug, into a global Phase 2 study enrolling approximately 210 participants across 20 sites in Taiwan, Sweden, and the United States. The approach is mechanistically distinct from the antibody therapies now in clinical use: rather than tagging amyloid for immune clearance, TML-6 targets the autophagy-lysosomal pathway, the intracellular system neurons use to degrade and recycle damaged proteins.
That distinction matters because the disease continues to progress even under treatment with agents like lecanemab, which received traditional FDA approval in July 2023, and donanemab, approved in July 2024. Both reduce amyloid burden and slow clinical decline in early-stage patients, but neither restores the cellular machinery responsible for ongoing protein clearance. Preclinical work on TML-6 has examined its effects on autophagy-lysosomal function in neurons and microglia alongside amyloid pathology and neuroinflammation, though translating that biology into a clinical signal remains the study’s central question.
The trial’s design is randomized, double-blind, and placebo-controlled. Participants receive TML-6 at 100 mg or 200 mg, or placebo, once daily for 52 weeks. The primary endpoint is change from baseline on the Clinical Dementia Rating Sum of Boxes, which captures both cognition and daily function. Secondary endpoints include four blood biomarkers: p-Tau 217, amyloid-beta, GFAP, and NfL. Henrik Zetterberg will lead biomarker analyses, and Barbara B. Bendlin will handle amyloid PET and MRI work, giving the study a biomarker infrastructure capable of detecting mechanistic effects even if the clinical signal is modest at this sample size.
Taiwan contributes nine of the 20 sites, making it the largest national cohort in the program. Sweden’s seven sites are anchored by Anne Börjesson-Hanson of Karolinska Institute, an investigator with primary investigator roles in more than 40 global trials. On October 4, she visits Taipei for the Taiwan Dementia Society Annual Scientific Meeting to work directly with the nine Taiwanese principal investigators. The p-Tau 217 trajectory over 52 weeks will be the number to watch: if TML-6 moves that biomarker in a direction consistent with improved lysosomal clearance, it gives the company a credible mechanistic story to carry into Phase 3 discussions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
